Skip to content
Pipeline

Therapeutic & Vaccine Candidates

Our fastpharming Manufacturing System enables speedy, scalable, safe and sustainable development of biopharmaceuticals. We’re advancing our pipeline of candidates in immuno-oncology, fibrotic and infectious diseases, as well as veterinary vaccines.

MFG Platform MFG
Human Health Programs
Hum Prgrms
Discovery
Disc
Pre-Clinical
Pre-Cl
Phase I
P I
Phase II
P II
FastPharming FastPharming FastPharming
Undisclosed Target 1
Oncology
Undisclosed Target 2
Oncology
Undisclosed Target 3
Oncology
ACE2-Fc
COVID-19
Animal Health Programs
Anml Prgrms
POC
POC
Pre-Clinical
P-C
Clinical Dev
CD
Product Registration
PR
FastPharming FastPharming FastPharming

Our focus in human health includes infectious diseases, where we are developing a vaccine for COVID-19, as well as an anti-fibrotic therapeutic candidate, IBIO-100, for idiopathic pulmonary fibrosis, amongst other indications. Some studies1 have shown that a number of patients recovering from COVID-19 have severe pulmonary fibrosis sequela.

Oncology is another focus, particularly in areas of high unmet medical need. We’re developing immunotherapy, IBIO-101, which has shown strong anti-tumor responses in preclinical models of disease. We expect our oncology pipeline to continue to grow with the in-house discovery capabilities established in San Diego in mid 2021, as well as with our partnership with RubrYc for access to their AI-enabled antibody design technologies.

In the field of animal health, we’re developing a vaccine candidate, IBIO-400, for classical swine fever – a contagious, often fatal disease affecting both feral and domesticated pigs.

References

  1. Zou, H., Li, Sq. Pulmonary fibrosis in critically ill patients with novel coronavirus pneumonia during the convalescent stage and a proposal for early intervention. Acta Pharmacol Sin (2020). https://doi.org/10.1038/s41401-020-00566-4
Top